Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Meta Expands AI Training With Employee Activity Tracking Tools 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
OKLAHOMA CITY, March 14, 2017 -- Cytovance® Biologics, a leading CDMO who provides unparalleled support to biopharmaceutical companies to move candidate molecules from the bench to commercial manufacturing, announces today that it has received a CMO Leadership Award in three categories; Quality, Reliability and Compatibility, which will be given at the CMO Leadership Awards Ceremony to be held March 22, 2017, at the W Hotel in New York City, NY.
“Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Executive Editor, Life Science Leader magazine and OutsourcedPharma.com. “Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the 6 critical categories of capabilities, compatibility, expertise, quality, reliability and development. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”
“We are honored to be awarded as a leader in the categories of Quality, Reliability and Compatibility by our clients in the CDMO marketplace,” stated Darren Head, President and CEO of Cytovance. “Cytovance Biologics proudly employs a highly experienced team, and we remain ever-cognizant of the significance of providing unparalleled service to our clients. We accept this award as a testament of the dedication and hard work of many within our remarkable company."
About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Contact: Cheryl Soerensen [email protected] 405.319.8310
